Supernus Pharmaceuticals Inc. (SUPN) Whale Options Tug-of-War, Max Pain & Unusual Sweeps
Supernus Pharmaceuticals Inc. (SUPN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Active Strike Call vs. Put Concentration Ladder (SUPN)
Practice in Our Weekly $100,000 Prop Arena Before Risking Personal Capital
Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.
Whale Flow & Momentum Playbook: Trading SUPN & AI Leaders Without Chasing Tops
- ✓Exact institutional whale strikes & implied earnings range on SUPN this week
- ✓How active traders scale setups using funded prop-firm accounts instead of risking savings
- ✓Free bonus: instant RQD Rating Flip alerts on all tracked momentum leaders
SUPN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SUPN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SUPN. Explore sector supply chains on /butterfly.
SUPN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is SUPN's options max pain and whale flow sentiment?
Unusual options sweeps in SUPN show 55% bullish call premium versus 45% put premium, centered near a $41 max-pain strike.